解决炎症：在 2 型糖尿病及其相关肾脏并发症中，促解决脂质的治疗潜力。
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.
机构信息
UCD Diabetes Research Centre, UCD Conway Institute, School of Medicine and Medical Sciences, University College Dublin Dublin, Ireland.
出版信息
Front Immunol. 2012 Oct 18;3:318. doi: 10.3389/fimmu.2012.00318. eCollection 2012.
Abstract
The role of inflammation in the pathogenesis of type 2 diabetes mellitus (T2DM) and its associated complications is increasingly recognized. The resolution of inflammation is actively regulated by endogenously produced lipid mediators such as lipoxins, resolvins, protectins, and maresins. Here we review the potential role of these lipid mediators in diabetes-associated pathologies, specifically focusing on adipose inflammation and diabetic kidney disease, i.e., diabetic nephropathy (DN). DN is one of the major complications of T2DM and we propose that pro-resolving lipid mediators may have therapeutic potential in this context. Adipose inflammation is also an important component of T2DM-associated insulin resistance and altered adipokine secretion. Promoting the resolution of adipose inflammation would therefore likely be a beneficial therapeutic approach in T2DM.
摘要
炎症在 2 型糖尿病（T2DM）及其相关并发症的发病机制中的作用正日益受到重视。内源性产生的脂质介质如脂氧素、消退素、保护素和maresin 可积极调节炎症的消退。在这里，我们综述了这些脂质介质在与糖尿病相关的病理中的潜在作用，特别是在脂肪炎症和糖尿病肾病（DN），即糖尿病肾病方面。DN 是 T2DM 的主要并发症之一，我们提出，促解决的脂质介质在这种情况下可能具有治疗潜力。脂肪炎症也是 T2DM 相关胰岛素抵抗和改变的脂肪因子分泌的一个重要组成部分。因此，促进脂肪炎症的消退可能是 T2DM 的一种有益的治疗方法。
相似文献
1
Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications.解决炎症：在 2 型糖尿病及其相关肾脏并发症中，促解决脂质的治疗潜力。
Front Immunol. 2012 Oct 18;3:318. doi: 10.3389/fimmu.2012.00318. eCollection 2012.
2
Mesenchymal Stem Cells Reverse Diabetic Nephropathy Disease via Lipoxin A4 by Targeting Transforming Growth Factor β (TGF-β)/smad Pathway and Pro-Inflammatory Cytokines.间质干细胞通过靶向转化生长因子 β（TGF-β）/smad 通路和促炎细胞因子逆转糖尿病肾病。
Med Sci Monit. 2019 Apr 26;25:3069-3076. doi: 10.12659/MSM.914860.
3
Pro-resolving lipid mediators: Agents of anti-ageing?促炎脂质介质：抗衰老的手段？
Semin Immunol. 2018 Dec;40:36-48. doi: 10.1016/j.smim.2018.09.002. Epub 2018 Oct 4.
4
Resolution of Inflammation after Skeletal Muscle Ischemia-Reperfusion Injury: A Focus on the Lipid Mediators Lipoxins, Resolvins, Protectins and Maresins.骨骼肌缺血再灌注损伤后炎症的消退：聚焦脂质介质脂氧素、消退素、保护素和促消退介素
Antioxidants (Basel). 2022 Jun 20;11(6):1213. doi: 10.3390/antiox11061213.
5
Immuno-Resolving Ability of Resolvins, Protectins, and Maresins Derived from Omega-3 Fatty Acids in Metabolic Syndrome.ω-3 脂肪酸衍生的 resolvins、protectins 和maresins 的免疫调节能力在代谢综合征中的作用。
Mol Nutr Food Res. 2020 Feb;64(4):e1900824. doi: 10.1002/mnfr.201900824. Epub 2019 Dec 15.
6
Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes.炎症和解决的脂质介质在结核和结核-糖尿病个体中。
Prostaglandins Other Lipid Mediat. 2020 Apr;147:106398. doi: 10.1016/j.prostaglandins.2019.106398. Epub 2019 Nov 11.
7
Novel mediators and mechanisms in the resolution of infectious inflammation: evidence for vagus regulation.感染性炎症消退中的新型介质和机制：迷走神经调节的证据。
J Intern Med. 2019 Sep;286(3):240-258. doi: 10.1111/joim.12871. Epub 2019 Jan 18.
8
Specialized Pro-resolving Lipid Mediators: Modulation of Diabetes-Associated Cardio-, Reno-, and Retino-Vascular Complications.特殊促消退脂质介质：对糖尿病相关心脏、肾脏和视网膜血管并发症的调节作用
Front Pharmacol. 2018 Dec 19;9:1488. doi: 10.3389/fphar.2018.01488. eCollection 2018.
9
Specialized pro-resolving mediators in cardiovascular diseases.心血管疾病中的特异性促解决介质。
Mol Aspects Med. 2017 Dec;58:65-71. doi: 10.1016/j.mam.2017.02.003. Epub 2017 Feb 28.
10
Lipoxin A4 attenuates adipose inflammation.脂氧素 A4 可减轻脂肪组织炎症。
FASEB J. 2012 Oct;26(10):4287-94. doi: 10.1096/fj.12-208249. Epub 2012 Jun 14.
引用本文的文献
1
Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy.糖尿病肾病发病机制中的免疫炎症与代谢相互作用
Front Endocrinol (Lausanne). 2025 Jul 8;16:1602594. doi: 10.3389/fendo.2025.1602594. eCollection 2025.
2
Cardiovascular/Stroke Risk Stratification in Diabetic Foot Infection Patients Using Deep Learning-Based Artificial Intelligence: An Investigative Study.使用基于深度学习的人工智能对糖尿病足感染患者进行心血管/中风风险分层：一项调查研究。
J Clin Med. 2022 Nov 19;11(22):6844. doi: 10.3390/jcm11226844.
3
Therapeutic Potential of Lipoxin A in Chronic Inflammation: Focus on Cardiometabolic Disease.脂氧素A在慢性炎症中的治疗潜力：聚焦于心脑血管代谢疾病
ACS Pharmacol Transl Sci. 2020 Jan 17;3(1):43-55. doi: 10.1021/acsptsci.9b00097. eCollection 2020 Feb 14.
4
Actions of annatto-extracted tocotrienol supplementation on obese postmenopausal women: study protocol for a double-blinded, placebo-controlled, randomised trial.姜黄提取物生育三烯酚补充剂对肥胖绝经后妇女的作用：一项双盲、安慰剂对照、随机试验的研究方案。
BMJ Open. 2020 Mar 8;10(3):e034338. doi: 10.1136/bmjopen-2019-034338.
5
The effect of western diet on mice brain lipid composition.西方饮食对小鼠脑脂质成分的影响。
Nutr Metab (Lond). 2019 Nov 27;16:81. doi: 10.1186/s12986-019-0401-4. eCollection 2019.
6
Mesenchymal Stem Cells Reverse Diabetic Nephropathy Disease via Lipoxin A4 by Targeting Transforming Growth Factor β (TGF-β)/smad Pathway and Pro-Inflammatory Cytokines.间质干细胞通过靶向转化生长因子 β（TGF-β）/smad 通路和促炎细胞因子逆转糖尿病肾病。
Med Sci Monit. 2019 Apr 26;25:3069-3076. doi: 10.12659/MSM.914860.
7
New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration.新型促解决 n-3 介质将传染性炎症的解决与组织再生联系起来。
Mol Aspects Med. 2018 Dec;64:1-17. doi: 10.1016/j.mam.2017.08.002. Epub 2017 Sep 1.
8
MiR-30a targets IL-1α and regulates islet functions as an inflammation buffer and response factor.miR-30a 通过靶向 IL-1α 作为炎症缓冲和反应因子调节胰岛功能。
Sci Rep. 2017 Jul 13;7(1):5270. doi: 10.1038/s41598-017-05560-1.
9
Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.特殊的促分解介质及其受体的结构阐明和生理功能。
Mol Aspects Med. 2017 Dec;58:114-129. doi: 10.1016/j.mam.2017.03.005. Epub 2017 Mar 31.
10
Maresin 1 Mitigates High Glucose-Induced Mouse Glomerular Mesangial Cell Injury by Inhibiting Inflammation and Fibrosis.maresin 1通过抑制炎症和纤维化减轻高糖诱导的小鼠肾小球系膜细胞损伤。
Mediators Inflamm. 2017;2017:2438247. doi: 10.1155/2017/2438247. Epub 2017 Jan 15.
本文引用的文献
1
Antioxidants in kidney diseases: the impact of bardoxolone methyl.肾脏疾病中的抗氧化剂：巴多昔芬甲基的影响
Int J Nephrol. 2012;2012:321714. doi: 10.1155/2012/321714. Epub 2012 Jun 4.
2
Lipoxin A4 attenuates adipose inflammation.脂氧素 A4 可减轻脂肪组织炎症。
FASEB J. 2012 Oct;26(10):4287-94. doi: 10.1096/fj.12-208249. Epub 2012 Jun 14.
3
Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation.消退素E1和D1通过抑制局部成纤维细胞增殖来抑制梗阻性肾病中的间质纤维化。
J Pathol. 2012 Dec;228(4):506-19. doi: 10.1002/path.4050. Epub 2012 Nov 6.
4
Update on potential drugs for the treatment of diabetic kidney disease.治疗糖尿病肾病的潜在药物研究进展。
Clin Ther. 2012 Jun;34(6):1237-46. doi: 10.1016/j.clinthera.2012.04.026. Epub 2012 May 11.
5
Aspirin-triggered lipoxin A₄ attenuates lipopolysaccharide-induced intracellular ROS in BV2 microglia cells by inhibiting the function of NADPH oxidase.阿司匹林诱导的脂氧素 A₄ 通过抑制 NADPH 氧化酶的功能来减轻 LPS 诱导的 BV2 小胶质细胞内 ROS 的产生。
Neurochem Res. 2012 Aug;37(8):1690-6. doi: 10.1007/s11064-012-0776-3. Epub 2012 May 3.
6
Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus.白细胞介素-1 受体拮抗剂：2 型糖尿病的一种新疗法。
J Pharm Sci. 2012 May;101(5):1647-58. doi: 10.1002/jps.23057. Epub 2012 Jan 23.
7
Glycated haemoglobin--a marker and predictor of cardiovascular disease.糖化血红蛋白——心血管疾病的一个标志物及预测指标。
J Pak Med Assoc. 2011 Jul;61(7):690-5.
8
Diabetes: bardoxolone improves kidney function in type 2 diabetes.糖尿病：巴多昔芬可改善2型糖尿病患者的肾功能。
Nat Rev Nephrol. 2011 Aug 23;7(10):552-3. doi: 10.1038/nrneph.2011.114.
9
Bardoxolone methyl and kidney function in CKD with type 2 diabetes.巴多索隆甲和 2 型糖尿病 CKD 患者的肾功能。
N Engl J Med. 2011 Jul 28;365(4):327-36. doi: 10.1056/NEJMoa1105351. Epub 2011 Jun 24.
10
Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis.脂氧素 A4 和苯并脂氧素 A4 可减轻实验性肾纤维化。
FASEB J. 2011 Sep;25(9):2967-79. doi: 10.1096/fj.11-185017. Epub 2011 May 31.
Zotero 插件